Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Basecare Medical's quarterly market cap
increased
from Dec. 2024 (HK$749.5 Mil) to Jun. 2025 (HK$774.1 Mil) but then
declined
from Jun. 2025 (HK$774.1 Mil) to Dec. 2025 (HK$508.8 Mil).
Suzhou Basecare Medical's annual market cap
increased
from Dec. 2023 (HK$642.8 Mil) to Dec. 2024 (HK$749.5 Mil) but then
declined
from Dec. 2024 (HK$749.5 Mil) to Dec. 2025 (HK$508.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Suzhou Basecare Medical's Enterprise Value for Today is HK$267.2 Mil.
Suzhou Basecare Medical (HKSE:02170) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Suzhou Basecare Medical Market Cap Related Terms
Suzhou Basecare Medical Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02170 vs ABT, SYK, MDT: Market Cap Comparison
For the Medical Devices subindustry, Suzhou Basecare Medical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Basecare Medical Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's Market Cap distribution charts can be found below:
* The bar in red indicates where Suzhou Basecare Medical's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Suzhou Basecare Medical's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Basecare Medical (HKSE:02170) has a Market Cap of HK$382.9 Mil as of Aug. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Suzhou Basecare Medical and its competitors. According to the industry distribution chart, Suzhou Basecare Medical ranks #540 out of 861 companies in the Medical Devices & Instruments industry, placing it in the top 62.7%.
Is Suzhou Basecare Medical's Market Cap too high?
Suzhou Basecare Medical's current Market Cap is HK$382.9 Mil. Based on the distribution chart, Suzhou Basecare Medical ranks #540 out of 861 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Suzhou Basecare Medical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Suzhou Basecare Medical ranks #540 out of 861 companies for Market Cap. This places Suzhou Basecare Medical in the lower half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 119.44, based on 861 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Suzhou Basecare Medical and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current Market Cap is HK$382.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.93, compared to a current price of HK$1.40 — trading 52.2% below its estimated fair value. The current Market Cap is HK$382.9 Mil. Suzhou Basecare Medical's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current Market Cap is HK$382.9 Mil as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued.
The current stock price of HK$1.40 is trading 52.2% below its estimated GF Value™ of HK$2.93.
GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.
Key valuation signals for HKSE:02170:
Market Cap: HK$382.9 Mil
GF Value™: HK$2.93 vs. price of HK$1.40 (52.2% below fair value)
No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
70GF Score
Get the complete analysis for HKSE:02170
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02170 has been successfully added to your 
